Lance A. Liotta

Dr. Lance A. Liotta

Center for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, VA 20110, USA
orcid

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 December 2005 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
Lance A. LiottaLance A. Liotta
Lance A. Liotta
EPEmanuel F. Petricoin
Emanuel F. Petricoin
The low molecular weight region of the serum peptidome contains protein fragments derived from 2 sources: (a) high-abundance endogenous circulating proteins and (b) cell and tissue proteins. While some researchers have dismissed the serum peptidome as biological trash, recent work using mass spectrometry–based (MS-based) profiling has indicated that the peptidome may reflect biological events and contain diagnostic biomarkers. In this issue of the JCI, Villanueva et al. report on MS-based peptide profiling of serum samples from patients with advanced prostate, bladder, or breast cancer as well as from healthy controls. Surprisingly, the peptides identified as cancer-type–specific markers proved to be products of enzymatic breakdown generated after patient blood collection. The impact of these results on cancer biomarker discovery efforts is significant because it is widely believed that proteolysis occurring ex vivo should be suppressed because it destroys endogenous biomarkers. Villanueva et al. now suggest that this suppression may in fact be preventing biomarker generation.

1 January 2011 in Journal of Clinical Bioinformatics
Verified
Journal Article
Open access
PDF file
XWXiangdong Wang
Xiangdong Wang
Lance A. LiottaLance A. Liotta
Lance A. Liotta
Welcome to the open-access journal titled Journal of Clinical Bioinformatics (JCBi), a truly international journal devoted to clinical applications of bioinformatics, medical informatics and the development of bioinformatics tools, methodologies and approaches for clinical research. JCBi aims to discover how biological and medical informatics can be applied to the development of personalized healthcare, medication and therapies. The field of clinical bioinformatics includes the analysis of human microarray and other omics data, combination of bioinformatics and medical informatics, development of bioinformatics methodologies for clinical research, and human databases. JCBi also aims to establish a scientific channel to translate bioinformatics to clinical and medical application in order to better understand molecular and cellular mechanisms and therapies for human diseases. Clinical bioinformatics is a new emerging science combining clinical informatics, bioinformatics, medical informatics, information technology, mathematics, and omics science together. At the beginning of the 20 th century, clinical physicians needed to be informed and open to advances in omics technology despite the barriers which existed for physicians applying genetic tests, for example the low tolerance for uncertainty, negative attitudes about their responsibility for genetic counseling and testing, and unfamiliarity with ethical issues raised by testing [1]. Since the middle of the 20 th century, bioinformatics was suggested to be applied for clinical toxicology [2] and cancer [3]. One of the early studies on expressed sequence tags in human stem cells by bioinformatics was performed in 1998 [4], where near 10000 sequences were analyzed. Of these, 48% showed the identity to known genes in the GenBank database, 26.4% matched to the previously deposited in a public domain database, 14% were previously undescribed sequences, and the remaining 12% were mitochondrial DNA, ribosomal RNA, or repetitive sequences. At the

2 December 2010 in Nature Reviews Cancer
Verified
Journal Article
Closed access
PDF file
VEVirginia Espina
Virginia Espina
Lance A. LiottaLance A. Liotta
Lance A. Liotta

5 December 2013 in BMC Research Notes
Verified
Journal Article
Open access
PDF file
FHFrankie Ann Holmes
Frankie Ann Holmes
VEVirginia Espina
Virginia Espina
Lance A. LiottaLance A. Liotta
Lance A. Liotta
YNYasir M Nagarwala
Yasir M Nagarwala
MDMichael Danso
Michael Danso
JOJoyce A O’shaughnessy
Joyce A O’shaughnessy
To define protein molecular characteristics of tumor cells prior to, and immediately following, preoperative human epidermal growth factor receptor 2 (HER2)-targeted therapy that correlate with pathologic complete response (pCR) or non response (no pCR) to preoperative HER2-directed therapy and chemotherapy.

22 March 2018 in Expert Review of Proteomics
Verified
Journal Article
Closed access
BKBrianna Kim
Brianna Kim
RARobyn Araujo
Robyn Araujo
MHMarissa Howard
Marissa Howard
RMRuben Magni
Ruben Magni
Lance A. LiottaLance A. Liotta
Lance A. Liotta
ALAlessandra Luchini
Alessandra Luchini
Introduction: Mass spectrometry (MS) is the premier tool for discovering novel disease-associated protein biomarkers. Unfortunately, when applied to complex body fluid samples, MS has poor sensitivity for the detection of low abundance biomarkers (≪10 ng/mL), derived directly from the diseased tissue cells or pathogens. Areas covered: Herein we discuss the strengths and drawbacks of technologies used to concentrate low abundance analytes in body fluids, with the aim to improve the effective sensitivity for MS discovery. Solvent removal by dry-down or dialysis, and immune-depletion of high abundance serum or plasma proteins, is shown to have disadvantages compared to positive selection of the candidate biomarkers by affinity enrichment. A theoretical analysis of affinity enrichment reveals that the yield for low abundance biomarkers is a direct function of the binding affinity (Association/Dissociation rates) used for biomarker capture. In addition, a high affinity capture pre processing step can effectively dissociate the candidate biomarker from partitioning with high abundance proteins such as albumin. Expert commentary: Properly designed high affinity capture materials can enrich the yield of low abundance (0.1–10 picograms/mL) candidate biomarkers for MS detection. Affinity capture and concentration, as an upfront step in sample preparation for MS, combined with MS advances in software and hardware that improve the resolution of the chromatographic separation can yield a transformative new class of low abundance biomarkers predicting disease risk or disease latency.

4 November 2015 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
RMRuben Magni
Ruben Magni
BEBenjamin H. Espina
Benjamin H. Espina
KSKetul Shah
Ketul Shah
BLBenjamin Lepene
Benjamin Lepene
CMChristine Mayuga
Christine Mayuga
ALAlessandra Luchini
Alessandra Luchini
Prompt antibiotic treatment of early stage Lyme borreliosis (LB) prevents progression to severe multisystem disease. There is a clinical need to improve the diagnostic specificity of early stage Lyme assays in the period prior to the mounting of a robust serology response. Using a novel analyte harvesting nanotechnology, Nanotrap particles, we evaluated urinary Borrelia Outer surface protein A (OspA) C-terminus peptide in early stage LB before and after treatment, and in patients suspected of late stage disseminated LB. We employed Nanotrap particles to concentrate urinary OspA and used a highly specific anti-OspA monoclonal antibody (mAb) as a detector of the C-terminus peptides. We mapped the mAb epitope to a narrow specific OspA C-terminal domain OspA236-239 conserved across infectious Borrelia species but with no homology to human proteins and no cross-reactivity with relevant viral and non-Borrelia bacterial proteins. 268 urine samples from patients being evaluated for all categories of LB were collected in a LB endemic area. The urinary OspA assay, blinded to outcome, utilized Nanotrap particle pre-processing, western blotting to evaluate the OspA molecular size, and OspA peptide competition for confirmation. OspA test characteristics: sensitivity 1.7 pg/mL (lowest limit of detection), % coefficient of variation (CV) = 8 %, dynamic range 1.7–30 pg/mL. Pre-treatment, 24/24 newly diagnosed patients with an erythema migrans (EM) rash were positive for urinary OspA while false positives for asymptomatic patients were 0/117 (Chi squared p < 10−6). For 10 patients who exhibited persistence of the EM rash during the course of antibiotic therapy, 10/10 were positive for urinary OspA. Urinary OspA of 8/8 patients switched from detectable to undetectable following symptom resolution post-treatment. Specificity of the urinary OspA test for the clinical symptoms was 40/40. Specificity of the urinary OspA antigen test for later serology outcome was 87.5 % (21 urinary OspA positive/24 serology positive, Chi squared p = 4.072e−15). 41 of 100 patients under surveillance for persistent LB in an endemic area were positive for urinary OspA protein. OspA urinary shedding was strongly linked to concurrent active symptoms (e.g. EM rash and arthritis), while resolution of these symptoms after therapy correlated with urinary conversion to OspA negative.